MarketPulse
G

$GYRE

2 articles found
2 positive
0 negative
0 neutral
BenzingaBenzinga··Globe Newswire

Gyre Therapeutics Completes $300M Cullgen Acquisition, Eyes Fibrosis Market

Gyre Therapeutics completes all-stock acquisition of Cullgen for ~$300M, creating integrated biopharmaceutical company with U.S.-China operations and commercial-stage fibrosis drug.
GYREacquisitionclinical development
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Gyre Therapeutics Posts 10% Revenue Growth but Guides Lower Amid Strategic Pivot

Gyre Therapeutics posts 10% FY2025 revenue growth to $116.6M, guides 2026 lower due to regulatory prioritization and Cullgen acquisition for TPD expansion.
GYRErevenue guidanceclinical trial